(PCVX) Vaxcyte - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92243G1085

Stock: Vaccines, Pneumococcal, Bacterial, Protein

Total Rating 29
Risk 87
Buy Signal 0.18
Biotechnology +8.2
Biotechnology +6.2
Market Cap: 8,731m
Avg Trading Vol: 70.8M USD
ATR: 5.51%
Peers RS (IBD): 54.8
Risk 5d forecast
Volatility 48.1%
Relative Tail Risk -8.72%
Reward TTM
Sharpe Ratio 0.06
Alpha -36.29
Character TTM
Beta 0.988
Beta Downside 0.673
Drawdowns 3y
Max DD 76.22%
CAGR/Max DD 0.21

EPS (Earnings per Share)

EPS (Earnings per Share) of PCVX over the last years for every Quarter: "2021-03": -0.41, "2021-06": -0.46, "2021-09": -0.51, "2021-12": -0.55, "2022-03": -0.68, "2022-06": -0.8, "2022-09": -0.93, "2022-12": -1.02, "2023-03": -0.7, "2023-06": -0.7, "2023-09": -0.91, "2023-12": -1.82, "2024-03": -0.85, "2024-06": -1.1, "2024-09": -0.83, "2024-12": -1.0176, "2025-03": -1.04, "2025-06": -1.22, "2025-09": -1.56, "2025-12": -1.8,
EPS CAGR: -46.64%
EPS Trend: -64.7%
Last SUE: -0.97
Qual. Beats: 0

Revenue

Revenue of PCVX over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 14.446, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0,
Rev. CAGR: 0.00%
Rev. Trend: -2.8%
Last SUE: 0.00
Qual. Beats: 0

Description: PCVX Vaxcyte March 05, 2026

Vaxcyte, Inc. (PCVX) is a clinical-stage biotechnology company focused on developing vaccines for bacterial infectious diseases. The companys business model centers on advancing a pipeline of conjugate and novel protein vaccines.

Its primary vaccine candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine (PCV) targeting invasive pneumococcal disease (IPD) in infants. Vaxcyte also has VAX-31, a 31-valent PCV for adults and children, and several other vaccine candidates in development, including for Group A Streptococcus and periodontitis. The biotechnology sector is characterized by high research and development costs and a long development timeline for new products.

The company, incorporated in 2013 and headquartered in San Carlos, California, changed its name from SutroVax, Inc. in 2020. Understanding a companys pipeline and clinical trial stages is crucial; further research on platforms like ValueRay can provide detailed insights into these aspects.

Headlines to watch out for

VAX-24 clinical trial results impact stock valuation | Regulatory approval for VAX-24 drives market entry | Competition from established vaccine manufacturers | Pipeline development costs affect profitability | Future vaccine candidates expand market potential

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.22 > 0.02 and ΔFCF/TA -5.51 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.22 > 3% & CFO -655.6m > Net Income -766.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 7.91 > 1.5 & < 3
Outstanding Shares: last quarter (136.1m) vs 12m ago 10.78% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%)
Interest Coverage Ratio: -20.13 > 6 (EBITDA TTM -781.8m / Interest Expense TTM -40.1m)

Altman Z'' -7.17

A: 0.47 (Total Current Assets 1.63b - Total Current Liabilities 205.8m) / Total Assets 3.05b
B: -0.71 (Retained Earnings -2.15b / Total Assets 3.05b)
C: -0.25 (EBIT TTM -806.7m / Avg Total Assets 3.28b)
D: -5.97 (Book Value of Equity -2.15b / Total Liabilities 360.5m)
Altman-Z'' Score: -7.17 = D

Beneish M

DSRI: none (Receivables 46.6m/20.7m, Revenue 0.0/0.0)
GMI: 1.00 (fallback, negative margins)
AQI: 0.77 (AQ_t 0.30 / AQ_t-1 0.40)
SGI: none (Revenue 0.0 / 0.0)
TATA: -0.04 (NI -766.6m - CFO -655.6m) / TA 3.05b)
Beneish M-Score: cannot calculate (missing components)

What is the price of PCVX shares?

As of March 08, 2026, the stock is trading at USD 59.29 with a total of 1,407,885 shares traded.
Over the past week, the price has changed by -3.97%, over one month by +5.59%, over three months by +28.39% and over the past year by -20.75%.

Is PCVX a buy, sell or hold?

Vaxcyte has received a consensus analysts rating of 4.90. Therefore, it is recommended to buy PCVX.
  • StrongBuy: 9
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the PCVX price?

Issuer Target Up/Down from current
Wallstreet Target Price 109 83.8%
Analysts Target Price 109 83.8%

PCVX Fundamental Data Overview March 06, 2026

P/B = 3.0757
Revenue TTM = 0.0 USD
EBIT TTM = -806.7m USD
EBITDA TTM = -781.8m USD
Long Term Debt = 117.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.12m USD (from shortTermDebt, last quarter)
Debt = 228.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 54.9m USD (from netDebt column, last quarter)
Enterprise Value = 7.40b USD (8.73b + Debt 228.8m - CCE 1.56b)
Interest Coverage Ratio = -20.13 (Ebit TTM -806.7m / Interest Expense TTM -40.1m)
EV/FCF = -11.06x (Enterprise Value 7.40b / FCF TTM -669.3m)
FCF Yield = -9.05% (FCF TTM -669.3m / Enterprise Value 7.40b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.43 (Enterprise Value 7.40b / Total Assets 3.05b)
Interest Expense / Debt = 4.69% (Interest Expense 10.7m / Debt 228.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -637.3m (EBIT -806.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.91 (Total Current Assets 1.63b / Total Current Liabilities 205.8m)
Debt / Equity = 0.09 (Debt 228.8m / totalStockholderEquity, last quarter 2.69b)
Debt / EBITDA = -0.07 (negative EBITDA) (Net Debt 54.9m / EBITDA -781.8m)
Debt / FCF = -0.08 (negative FCF - burning cash) (Net Debt 54.9m / FCF TTM -669.3m)
Total Stockholder Equity = 2.96b (last 4 quarters mean from totalStockholderEquity)
RoA = -23.38% (Net Income -766.6m / Total Assets 3.05b)
RoE = -25.88% (Net Income TTM -766.6m / Total Stockholder Equity 2.96b)
RoCE = -26.19% (EBIT -806.7m / Capital Employed (Equity 2.96b + L.T.Debt 117.5m))
RoIC = -21.51% (negative operating profit) (NOPAT -637.3m / Invested Capital 2.96b)
WACC = 9.41% (E(8.73b)/V(8.96b) * Re(9.56%) + D(228.8m)/V(8.96b) * Rd(4.69%) * (1-Tc(0.21)))
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.16%
[DCF] Fair Price = unknown (Cash Flow -669.3m)
EPS Correlation: -64.67 | EPS CAGR: -46.64% | SUE: -0.97 | # QB: 0
Revenue Correlation: -2.80 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.85 | Chg7d=-0.253 | Chg30d=-0.253 | Revisions Net=+0 | Analysts=5
EPS current Year (2026-12-31): EPS=-7.39 | Chg7d=-1.210 | Chg30d=-1.172 | Revisions Net=-2 | Growth EPS=-31.3% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-7.29 | Chg7d=-0.140 | Chg30d=-0.146 | Revisions Net=+1 | Growth EPS=+1.4% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)

Additional Sources for PCVX Stock

Fund Manager Positions: Dataroma | Stockcircle